Gemici, AliihsanDogu, Mehmet HilmiTekinalp, AtakanAlacacioglu, InciGuney, TekinInce, IdrisGeduk, AyferCağlıyan, Gulsum AkgunMaral, SenemSerin, IstemiGunduz, ErenKarakus, VolkanBekoz, Huseyin SaffetEren, RafetGunes, Ahmet KursadSargin, Fatma DenizSevindik, Omur Gokmen2024-06-122024-06-122021-08-102152-2650https://doi.org/10.1016/j.clml.2021.04.004https://hdl.handle.net/11452/42062Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients with a median age of 67 years from different centers were included in the final analysis. Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML. Materials and Methods: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML. Results: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported. Conclusion: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML. (C) 2021 Elsevier Inc. All rights reserved.eninfo:eu-repo/semantics/openAccessLow-dose cytarabineOlder patientsBcl-2 inhibitionAzacitidineSurvivalCareAmlBcl2InhibitorVenetoclaxAcute myeloid leukemiaReal lifeScience & technologyLife sciences & biomedicineOncologyHematologyOncologyHematologyArticle000684596500017E686E69221810.1016/j.clml.2021.04.004